Contract development and manufacturing organisation and vaccine maker Bharat Biotech’s subsidiary Nucelion Therapeutics and VeGen Bio, a Hyderabad-based precision oncology company, will collaborate for the technology transfer, clinical manufacturing and commercial production of innovative cell therapies in India.As part of the agreement, Nucelion will serve as the technology transfer and clinical as well as commercial stage manufacturing partner for VeGen Bio’s lead candidate, VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma into its single-site GMP manufacturing facility. A first-in-India Phase 1/2 trial followed by targeted commercialisation of the product in 2028 figure in their plans.Therapeutic translation, process…